A clinical trial of hyperalimentation in children with metastatic malignancies

Authors

  • J. Van Eys MD, PhD,

    Corresponding author
    1. Department of Pediatrics, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas
    • The Department of Pediatrics, The University of Texas System Cancer Center, M.D. Anderson Hospital and Tumor Institute, Houston, TX 77030
    Search for more papers by this author
  • E. M. Copeland PhD,

    1. Department of Surgery, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas
    Search for more papers by this author
  • A. Cangir MD,

    1. Department of Pediatrics, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas
    Search for more papers by this author
  • G. Taylor MD,

    1. Department of Pediatrics, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas
    Search for more papers by this author
  • B. Teitell-Cohen RN,

    1. Department of Nursing, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas
    Search for more papers by this author
  • P. Carter RN,

    1. Department of Nutrition and Food Service, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas
    Search for more papers by this author
  • C. Ortiz RN

    1. Department of Nursing, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas
    Search for more papers by this author

Abstract

In a controlled, randomized prospective clinical trial the utility of intravenous hyperalimentation (IVH) in the administration of and tolerance to chemotherapy was tested. The conclusions reached were 1) IVH is safe with a tolerable infection rate; 2) infectious complications correlate significantly with the nutritional status of the patient, with the presence of IVH being only a secondary factor; 3) IVH may be used to rehabilitate patients nutritionally, even those on intensive chemoterhapy; 4) the ability to deliver chemotherapy to patients seems to be improved by IVH, especially in malnourished patients in a late stage of disease.

Ancillary